Characteristics and risk profile of psoriasis patients included in the Czech national registry BIOREP and a comparison with other registries

Int J Dermatol. 2017 Apr;56(4):428-434. doi: 10.1111/ijd.13543. Epub 2017 Feb 9.

Abstract

Background: BIOREP is a Czech registry of psoriatic patients on biological treatment in a clinical setting. We describe the characteristics of patients with psoriasis at the time of enrollment and present comparisons with published data from other national registries.

Methods: We analyzed the cohort of patients treated with biologics between May 2005 and May 2015. Demographic data, previous therapies, comorbidities, and severity of psoriasis were compared with data from other registries - DERMBIO, BIOBADADERM, BADBIR, and PSOBEST.

Results: A total of 1412 psoriatic patients initiating biological treatment were included with a predominance of males (63.4%). The mean patient age was 50.2 years, and approximately 70.5% of patients were either overweight or obese. The mean baseline Psoriasis Area and Severity Index was 19.8, and the Dermatology Life Quality Index was 16.6. More than one-third of patients (41.0%) reported a history of psoriatic arthritis, and a high proportion of patients (49.5%) with cardiovascular risk factors (hypertension [35.2%], hyperlipidemia [27.7%], diabetes mellitus [11.4%], coronary heart disease [4.9%], and obesity [15.2%]) were observed. Most of the patients had been previously treated with phototherapy (85.4%), acitretin (74.0%), methotrexate (65.7%), or cyclosporine (53.1%).

Conclusion: BIOREP is one of the first registries of patients with psoriasis treated with biologics in Central and Eastern Europe. Our results found a similar or higher prevalence of comorbidities, long disease duration, and high impact on the quality of life among patients included in Western European registries.

Publication types

  • Comparative Study

MeSH terms

  • Acitretin / therapeutic use
  • Adult
  • Biological Products / therapeutic use*
  • Body Mass Index
  • Comorbidity
  • Coronary Disease / epidemiology
  • Cyclosporine / therapeutic use
  • Czech Republic / epidemiology
  • Dermatologic Agents / therapeutic use
  • Diabetes Mellitus / epidemiology
  • Female
  • Humans
  • Hyperlipidemias / epidemiology
  • Hypertension / epidemiology
  • Keratolytic Agents / therapeutic use
  • Male
  • Methotrexate / therapeutic use
  • Middle Aged
  • Obesity / epidemiology*
  • Phototherapy
  • Prevalence
  • Psoriasis / drug therapy*
  • Psoriasis / epidemiology*
  • Psoriasis / therapy
  • Quality of Life
  • Registries
  • Retreatment
  • Retrospective Studies
  • Risk Factors
  • Severity of Illness Index

Substances

  • Biological Products
  • Dermatologic Agents
  • Keratolytic Agents
  • Cyclosporine
  • Acitretin
  • Methotrexate